H.C. Wainwright Lifts CRISPR Therapeutics' (CRSP) Price Target on CASGEVy Sales Growth

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood's Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock and raised the price target to $80 from $65. The price target adjustment follows the stock's strong performance, depicted by 41% year-to-date gain.

Likewise, the research firm has echoed CRISPR Therapeutics' second-quarter results, which showed a 114% quarter-over-quarter increase in CASGEVY sales to $30 million. The significant growth came from the treatment being infused in 16 patients, double the eight infusions done in the first quarter.

The number of infusions has been increasing steadily, from four patients in the fourth quarter of 2024 to one patient in the third quarter. Revenues have also increased steadily from $2 million in the third quarter of last year.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene-editing company focused on developing transformative, gene-based medicines for serious diseases. It utilizes a proprietary CRISPR/Cas9 platform to precisely edit DNA and target various diseases like hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.